Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) submitted its Monthly Return for Equity Issuer for the period ended 30 April 2026, confirming an unchanged share structure across both A and H shares.

Authorised Capital • Ordinary A shares remained at 737.90 million with a par value of RMB 1. • Ordinary H shares stayed at 123.12 million, also at RMB 1 par value. • Combined authorised share capital was RMB 861.03 million.

Issued and Treasury Shares • Issued (non-treasury) A shares were unchanged at 732.02 million; treasury A shares held steady at 5.88 million, keeping total issued A shares at 737.90 million. • Issued H shares were unchanged at 123.12 million, with no treasury balance. • No share options, warrants, convertibles, or other equity instruments were outstanding or exercised during the month.

Public Float Compliance • TIGERMED confirmed compliance with the Hong Kong Stock Exchange’s 5 % minimum public-float requirement for its H-share class.

Treasury-Share Background Repurchases conducted between May 2024 and February 2025 totalled 9.81 million A shares, of which 3.92 million were cancelled on 29 May 2025. The remaining 5.88 million A shares continue to be held in treasury, with no additional repurchase or cancellation activity recorded in April 2026.

Overall, TIGERMED’s April filing indicates a stable capital base, with no new share issuances, cancellations, or movements affecting its authorised or issued share counts during the month.